Future therapies for obesity.
gut hormones
obesity
pharmacotherapy
tirzepatide
Journal
Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
medline:
5
10
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management.
Identifiants
pubmed: 37524416
pii: 23/4/337
doi: 10.7861/clinmed.2023-0144
pmc: PMC10541050
doi:
Substances chimiques
Gastrointestinal Hormones
0
Glucagon-Like Peptide 1
89750-14-1
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337-346Informations de copyright
© Royal College of Physicians 2023. All rights reserved.
Références
N Engl J Med. 2021 Aug 5;385(6):503-515
pubmed: 34170647
Clin Sci (Lond). 2011 Aug;121(3):107-17
pubmed: 21332446
Diabetologia. 2022 Sep;65(Suppl 1):1-469
pubmed: 35920845
N Engl J Med. 2022 Jul 21;387(3):205-216
pubmed: 35658024
Nat Med. 2022 Oct;28(10):2083-2091
pubmed: 36216945
Nat Rev Endocrinol. 2010 Dec;6(12):689-97
pubmed: 20957001
Lancet. 2021 May 8;397(10286):1736-1748
pubmed: 33894838
Lancet. 2021 Mar 13;397(10278):971-984
pubmed: 33667417
J Intern Med. 2020 May;287(5):546-557
pubmed: 32128923
Lancet. 2023 Apr 1;401(10382):1116-1130
pubmed: 36774932
J Obes Metab Syndr. 2023 Mar 30;32(1):25-45
pubmed: 36750526
Endocr Rev. 2020 Jan 1;41(1):
pubmed: 31511854
Ann Surg. 2021 Dec 1;274(6):e1269-e1276
pubmed: 32187033
Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406
pubmed: 35468325
Diabetes Obes Metab. 2021 Aug;23(8):1795-1805
pubmed: 33822469
Diabetes Care. 2021 Jun;44(6):1433-1442
pubmed: 34016612
Surg Obes Relat Dis. 2020 Aug;16(8):1133-1144
pubmed: 32446593
Nat Med. 2022 Mar;28(3):591-598
pubmed: 35210595
JAMA. 2018 Oct 16;320(15):1560-1569
pubmed: 30326125
N Engl J Med. 2015 Jul 2;373(1):11-22
pubmed: 26132939
N Engl J Med. 2016 Nov 10;375(19):1834-1844
pubmed: 27633186
Cell Metab. 2006 Mar;3(3):153-65
pubmed: 16517403
Ther Adv Endocrinol Metab. 2019 Sep 23;10:2042018819875407
pubmed: 31579501
Lancet Diabetes Endocrinol. 2018 Mar;6(3):197-207
pubmed: 29329975
Clin Obes. 2019 Aug;9(4):e12323
pubmed: 31183988
Mol Metab. 2022 Sep;63:101533
pubmed: 35809773
Sci Transl Med. 2013 Oct 30;5(209):209ra151
pubmed: 24174327
Diabetologia. 2022 Dec;65(12):1925-1966
pubmed: 36151309
Clin Obes. 2021 Apr;11(2):e12432
pubmed: 33475255
Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-785
pubmed: 36152639
Diabetes Obes Metab. 2022 Aug;24(8):1553-1564
pubmed: 35441470
Diabetes Care. 2023 May 1;46(5):998-1004
pubmed: 36857477
Lancet. 2021 Jul 10;398(10295):143-155
pubmed: 34186022
Surg Obes Relat Dis. 2018 May;14(5):708-714
pubmed: 29776493
J Obes Metab Syndr. 2021 Dec 30;30(4):320-325
pubmed: 34929674
Ann Intern Med. 2018 Dec 4;169(11):741-750
pubmed: 30383139
Eur J Intern Med. 2021 Nov;93:3-7
pubmed: 33461826
Clin Obes. 2021 Apr;11(2):e12433
pubmed: 33475251
N Engl J Med. 2017 Aug 31;377(9):839-848
pubmed: 28854085
Cell Metab. 2022 Sep 6;34(9):1234-1247.e9
pubmed: 35985340
Cardiovasc Res. 2022 Nov 30;:
pubmed: 36448672
Lancet. 2021 Dec 11;398(10317):2160-2172
pubmed: 34798060
Mol Metab. 2021 Apr;46:101090
pubmed: 32987188
Obes Rev. 2017 Jul;18(7):715-723
pubmed: 28489290
Obesity (Silver Spring). 2022 Apr;30(4):802-840
pubmed: 35333446
Lancet. 2021 Nov 13;398(10313):1811-1824
pubmed: 34672967
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Trends Endocrinol Metab. 2020 Jun;31(6):410-421
pubmed: 32396843
JAMA Netw Open. 2021 Jan 4;4(1):e2033457
pubmed: 33439265
Lancet Diabetes Endocrinol. 2022 Jun;10(6):418-429
pubmed: 35468322
Diabetes Obes Metab. 2017 Mar;19(3):336-347
pubmed: 27860132
Diabetes Obes Metab. 2020 Aug;22(8):1263-1277
pubmed: 32267058
Lancet Diabetes Endocrinol. 2019 Jul;7(7):549-559
pubmed: 31174993
BMJ Open. 2020 Feb 13;10(2):e034137
pubmed: 32060156
Lancet. 2022 Nov 26;400(10366):1869-1881
pubmed: 36354040
Lancet. 2021 Aug 14;398(10300):583-598
pubmed: 34370970
JAMA. 2022 Feb 8;327(6):534-545
pubmed: 35133415
Nat Med. 2021 Jun;27(6):1079-1087
pubmed: 34127852